ReviewJournal of orthopaedic translation2025
Forkhead box O proteins in chondrocyte aging and diseases.
Review in Journal of orthopaedic translation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bioenergetic Materials for Tissue Regeneration: Modulating Metabolism to Promote Cellular Anabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Progress in research on the association between mesenchymal stem cell senescence and knee osteoarthritis.Journal of orthopaedic surgery and research · 2026Review
- Research progress on cellular senescence in the pathogenesis and treatment of osteoarthritis and temporomandibular joint osteoarthritis.Journal of oral & facial pain and headache · 2026Review
- Identification of Key Osteoarthritis-Associated Genes Based on DNA Methylation.International journal of molecular sciences · 2026Article
- Mechanism of platelet-rich plasma inhibiting inflammatory response, oxidative stress, and senescence in synovial fibroblasts of patients with knee osteoarthritis via UBE2C based on transcriptome sequencing analysis.Journal of bioenergetics and biomembranes · 2026Article
- Nanotherapeutic Strategies for Osteoarthritis: Targeting Aging, Metabolism and Inflammation.International journal of nanomedicine · 2026Review
- From scientific discovery to orthopaedic clinical innovation.Journal of orthopaedic translation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As people age, the progressive loss of cartilage integrity occurs, accompanied by a decline in the capacity to repair. This results in decreased resilience and increased susceptibility of cartilage to various physiological stressors, which raises the risk of developing osteoarthritis (OA). Therefore, restoring the regenerative capacity of chondrocytes and slowing down the aging process could be promising therapeutic strategies to mitigate or even reverse age-related joint diseases. Forkhead box class O (FoxO) proteins are a family of transcription factors that play a crucial role in various cellular processes linked to aging. Their significant functions in cell cycle regulation, apoptosis, and resistance to oxidative stress highlight their importance in maintaining cellular homeostasis and promoting longevity. In this review, we introduce the structures and functions of FoxO proteins in chondrocytes, focusing on their spatiotemporal regulation of epigenetics during chondrocyte differentiation stages in different layers. The critical roles of FoxO proteins in maintaining chondrocyte homeostasis are summarized, alongside a discussion of how FoxO dysfunction contributes to aging and OA. Furthermore, therapeutic strategies targeting FoxO proteins to mitigate aging-related cartilage degradation and decelerate OA progression are explored. Finally, potential directions for future research are proposed to deepen the current understanding of FoxO proteins. The translational potential of this article: FoxO transcription factors, especially FoxO1 and FoxO3, are promising therapeutic targets for promoting longevity, stimulating cartilage regeneration, and treating aging-related diseases like OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.